Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-08-30 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
第一届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting, including approval of the 2023 semi-annual report, nomination of board candidates, amendments to the company charter, and proposals for a shareholders meeting. It includes voting results and references to related announcements and reports published elsewhere. The content focuses on board decisions and management matters rather than presenting financial statements or full reports. The document length is 2925 characters, which is relatively short and mainly serves as a formal announcement of board meeting outcomes. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related board resolutions.
2023-08-30 Chinese
关于参加2023年半年度制药及生物制品行业集体业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in a 2023 semi-annual industry collective performance explanation meeting organized by the Shanghai Stock Exchange. It references the company's 2023 semi-annual report but does not contain the report itself or detailed financial data. The document mainly informs investors about the timing, format, and participation details of an investor presentation event related to the half-year results. The document length is short (1261 characters) and serves as a notice for an upcoming investor interaction session rather than the report or transcript itself. Therefore, it fits best as an Investor Presentation (IP) announcement or notice rather than a full Interim Report (IR) or Call Transcript (CT). Given the detailed description of the investor meeting and interaction, the classification as Investor Presentation (IP) is most appropriate with high confidence.
2023-08-30 Chinese
关于调整董事会人数及修订《公司章程》并办理工商登记变更的公告
Board/Management Information Classification · 100% confidence The document is an announcement from the company 海创药业股份有限公司 regarding adjustments to the number of board members and revisions to the company's Articles of Association (公司章程). It details changes in board size, updates to shareholder names, and amendments to governance documents. The document is a formal announcement of board and governance changes, not a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a call transcript or voting result. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-08-30 Chinese
独立董事候选人声明（魏于全）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate of a company, detailing qualifications, compliance with regulatory requirements, and commitments related to the role. It is not a financial report, earnings release, or any form of regulatory filing about financial performance or corporate governance changes. It is a formal statement related to board/management information, specifically about the nomination and qualifications of a board member candidate. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on the candidate's declaration, not an announcement or report publication.
2023-08-30 Chinese
独立董事候选人声明（彭永臣）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate of a company, detailing qualifications, independence criteria, and compliance with regulatory requirements. It is a formal statement related to board/management matters, specifically about the nomination and qualifications of a board member. It does not contain financial data, audit information, or report publication announcements. It is not a report or announcement of voting results but a declaration related to board membership. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on director candidacy and qualifications, confirming this classification.
2023-08-30 Chinese
海创药业股份有限公司董事会议事规则（2023年8月修订）
Governance Information Classification · 95% confidence The document is titled "董事会议事规则" which translates to "Board Meeting Rules" or "Rules of Procedure for the Board of Directors". It details the composition, powers, authorization, meeting procedures, and responsibilities of the board of directors and the board secretary of the company 海创药业股份有限公司. The content is focused on governance structure, board meeting protocols, and internal rules rather than financial data, audit results, or shareholder meeting materials. It does not contain financial statements or earnings data, nor is it an announcement or transcript. It is a governance document outlining internal rules and practices of the board. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, supporting a high confidence classification.
2023-08-30 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.